Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Test System Development
2.2. Strain Phenotypic Testing
2.3. Test System Performance Evaluation
3. Results
3.1. Test System Development
3.2. Testing of Patient Samples
3.2.1. Molecular Resistance to Clarithromycin
3.2.2. Molecular Resistance to Levofloxacin
4. Discussion
5. Conclusions
6. Patents
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y. Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2019, 8, 420–429. [Google Scholar] [CrossRef] [PubMed]
- Mezmale, L.; Coelho, L.G.; Bordin, D.; Leja, M. Epidemiology of Helicobacter pylori. Helicobacter 2020, 9, 25. [Google Scholar] [CrossRef] [PubMed]
- Mladenova, I. Review—Epidemiology of Helicobacter pylori infection. Microb. Health Dis. 2023, 5, e913. [Google Scholar] [CrossRef]
- Sugano, K.; Tack, J.; Kuipers, E.J.; Graham, D.Y.; El-Omar, E.M.; Miura, S.; Haruma, K.; Asaka, M.; Uemura, N.; Malfertheiner, P. Kyoto Global Consensus Report on Helicobacter pylori gastritis. Gut 2015, 64, 1353–1367. [Google Scholar] [CrossRef]
- Tran, V.; Saad, T.; Tesfaye, M.; Walelign, S.; Wordofa, M.; Abera, D.; Desta, K.; Tsegaye, A.; Ay, A.; Taye, B. Analysis of risk factors of (H. pylori) and prediction of prevalence: Machine learning approach: Infectious diseases. Gut 2022, 22, 655. [Google Scholar]
- Noto, J.M.; Rose, K.L.; Hachey, A.J.; Delgado, A.G.; Romero-Gallo, J.; Wroblewski, L.E.; Schneider, B.G.; Shah, S.C.; Cover, T.L.; Wilson, K.T.; et al. Carcinogenic strains of Helicobacter pylori selectively dysregulate the stomach proteome In Vivo, which may be associated with the progression of gastric cancer. Mol. Cell Proteom. 2019, 18, 352–371. [Google Scholar] [CrossRef] [PubMed]
- Elbehiry, A.; Marzouk, E.; Aldubaib, M.; Abalkhail, F.; Anagreyyah, S.; Anajirih, N.; Almuzaini, A.M.; Rawway, M.; Alfadhel, A.; Draz, A.; et al. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics 2023, 12, 191. [Google Scholar] [CrossRef]
- Huang, R.J.; Epplein, M.; Hamashima, C.; Choi, I.J.; Lee, E.; Deapen, D.; Woo, Y.; Tran, T.; Shah, S.C.; Inadomi, J.M.; et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin. Gastroenterol. Hepatol. 2022, 20, 2218–2228. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Megraud, F.; Bruyndonckx, R.; Coenen, S.; Wittkop, L.; Huang, T.D.; Hoebeke, M.; Bénéjat, L.; Lehours, P.; Goossens, H.; Glupczynski, Y.; et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021, 70, 1815–1822. [Google Scholar] [CrossRef] [PubMed]
- Nyssen, O.P.; Vaira, D.; Tepes, B.; Kupcinskas, L.; Bordin, D.; Pérez-Aisa, A.; Gasbarrini, A.; Castro-Fernández, M.; Bujanda, L.; Garre, A. Hp-EuReg Investigators. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). J. Clin. Gastroenterol. 2022, 2, 98–108. [Google Scholar] [CrossRef]
- Bujanda, L.; Nyssen, O.P.; Vaira, D.; Saracino, L.M.; Fiorini, G.; Lerang, F.; Georgopoulos, S.; Tepes, B.; Heluwaert, F.; Antonio Gasbarrini, A. The Hp-EuReg Investigators. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics 2021, 9, 1058. [Google Scholar]
- Li, Y.; Choi, H.; Leung, K.; Jiang, F.; Graham, D.Y.; Leung, W.K. Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023, 8, 553–564. [Google Scholar] [CrossRef] [PubMed]
- Bordin, D.; Morozov, S.; Plavnik, R.; Bakulina, N.; Voynovan, I.; Skibo, I.; Isakov, V.; Bakulin, I.; Andreev, D.; Maev, I. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter 2022, 27, e12924. [Google Scholar] [CrossRef] [PubMed]
- Malfertheiner, P.; Megraud, F.; Rokkas, T.; Gisbert, J.P.; Liou, J.M.; Schulz, C.; Gasbarrini, A.; Hunt, R.H.; Leja, M.; O’Morain, C.; et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut 2022, 71, 1724–1762. [Google Scholar] [CrossRef] [PubMed]
- De Brito, B.B.; Da Silva, F.A.F.; Soares, A.S.; Pereira, V.A.; Santos, M.L.C.; Sampaio, M.M.; Neves, P.H.M.; De Melo, F.F. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J. Gastroenterol. 2019, 25, 5578–5589. [Google Scholar] [CrossRef] [PubMed]
- Kotilea, K.; Bontems, P.; Touati, E. Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. Adv. Exp. Med. Biol. 2019, 11, 17–33. [Google Scholar]
- Liou, J.-M.; Malfertheiner, P.; Lee, Y.-C.; Sheu, B.-S.; Sugano, K.; Cheng, H.-C.; Yeoh, K.-G.; Hsu, P.-I.; Goh, K.-L.; Mahachai, V.; et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus. Gut 2020, 69, 2093–2112. [Google Scholar] [CrossRef] [PubMed]
- Ng, H.-Y.; Leung, W.K.; Cheung, K.-S. Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection. Int. J. Mol. Sci. 2023, 24, 11708. [Google Scholar] [CrossRef] [PubMed]
- Puah, S.M.; Goh, K.L.; Ng, H.K.; Chua, K.H. The current state of resistance of Helicobacter pylori to clarithromycin and levofloxacin in Malaysia–Results of a molecular study. PeerJ 2021, 1, 12. [Google Scholar]
- Li, Y.; Lv, T.; He, C.; Wang, H.; Cram, D.S.; Zhou, L.; Zhang, J.; Jiang, W. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathog. 2020, 7, 10–12. [Google Scholar] [CrossRef]
- Ziver-Sarp, T.; Yuksel-Mayda, P.; Saribas, S.; Demiryas, S.; Gareayaghi, N.; Ergin, S.; Tasci, I.; Ozbey, D.; Bal, K.; Erzin, Y. Point mutations at gyrA and gyrB genes of levofloxacin resistant Helicobacter pylori strains and dual resistance with clarithromycin. Clin. Lab. 2021, 67, 10. [Google Scholar] [CrossRef] [PubMed]
- Srisuphanunt, M.; Wilairatana, P.; Kooltheat, N.; Duangchan, T.; Katzenmeier, G.; Rose, J.B. Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections. Trop. Med. Infect. Dis. 2023, 8, 163. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, F.; Suzuki, S.; Nagai, N.; Mochida, K.; Morishita, T. Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments. Gut Liver 2023, 17, 684. [Google Scholar] [CrossRef] [PubMed]
- Maev, I.V. Helicobacter pylori Infection: Monograph; GEOTAR-Media: Moscow, Russia, 2016; p. 256. [Google Scholar]
- Pei, A.; Nossa, C.W.; Chokshi, P.; Blaser, M.J.; Yang, L.; Rosmarin, D.M.; Pei, Z. Diversity of 23S rRNA Genes within Individual Prokaryotic Genomes. PLoS ONE 2009, 4, e5437. [Google Scholar] [CrossRef] [PubMed]
- Medakina, I.; Tsapkova, L.; Polyakova, V.; Nikolaev, S.; Yanova, T.; Dekhnich, N.; Khatkov, I.; Bordin, D.; Bodunova, N. Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods. Int. J. Mol. Sci. 2023, 24, 9433. [Google Scholar] [CrossRef] [PubMed]
- Greenhalgh, T. How to read a paper. Papers that report diagnostic or screening tests. BMJ 1997, 315, 540–543, Erratum in BMJ 1997, 315, 942; Erratum in: BMJ 1998, 316, 225. [Google Scholar] [PubMed] [PubMed Central]
- Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI supplement M100 Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
- Hulten, K.G.; Genta, R.M.; Kalfus, I.N.; Zhou, Y.; Zhang, H.; Graham, D.Y. Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology 2021, 161, 1433–1442. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Alavifard, H.; Mirzaei, N.; Yadegar, A.; Baghaei, K.; Smith, S.M.; Sadeghi, A.; Zali, M.R. Investigation of mutations associated with clarithromycin resistance and Helicobacter pylori virulence genotypes isolated from the Iranian population: A cross-sectional study. Curr. Microbiol. 2021, 78, 244–254. [Google Scholar] [CrossRef]
- Chtourou, L.; Moalla, M.; Mnif, B.; Smaoui, H.; Gdoura, H.; Boudabous, M.; Mnif, L.; Amouri, A.; Hammami, A.; Tahri, N. Prevalence of Helicobacter pylori resistance to clarithromycin in Tunisia. J. Med. Microbiol. 2022, 8, 71. [Google Scholar] [CrossRef]
- Tran, V.H.; Ha, T.M.T.; Le, P.T.Q.; Phan, T.N.; Tran, T.N.H. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin-resistant phenotype in central Vietnam. J. Glob. Antimicrob. Resist. 2019, 3, 87–91. [Google Scholar] [CrossRef] [PubMed]
- Subsomwong, P.; Doohan, D.; Fauzia, K.A.; Akada, J.; Matsumoto, T.; Yee, T.T.; Htet, K.; Waskito, L.A.; Tuan, V.; Uchida, T. Next-Generation Sequencing-Based Study of Helicobacter pylori Isolates from Myanmar and Their Susceptibility to Antibiotics. Microorganisms 2022, 10, 196. [Google Scholar] [CrossRef] [PubMed]
- De Palma, G.Z.; Mendiondo, N.; Wonaga, A.; Viola, L.; Ibarra, D.; Campitelli, E.; Salim, N.; Corti, R.; Goldman, C.; Catalano, M. Occurrence of mutations in the antimicrobial target genes related to levofloxacin, clarithromycin, and amoxicillin resistance in Helicobacter pylori isolates from Buenos Aires city. Microb. Drug Resist. 2016, 23, 351–358. [Google Scholar] [CrossRef] [PubMed]
- Garcia, M.; Raymond, J.; Garnier, M.; Cremniter, J.; Burucoa, C. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob. Agents Chemother. 2012, 56, 550–551. [Google Scholar] [CrossRef] [PubMed]
- Albasha, A.M.; Elnosh, M.M.; Osman, E.H.; Zeinalabdin, D.M.; Fadl, A.A.M.; Ali, M.A.; Altayb, H.N. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiol. 2021, 2, 21–38. [Google Scholar] [CrossRef] [PubMed]
- Domanovich-Asor, T.; Motro, Y.; Khalfin, B.; Craddock, H.A.; Peretz, A.; Moran-Gilad, J. Genomic Analysis of Antimicrobial Resistance Genotypeto-Phenotype Agreement in Helicobacter pylori. Microorganisms 2021, 9, 2. [Google Scholar] [CrossRef]
Antibiotic | Minimum Suppressive Concentration, mg/L | |
---|---|---|
Sensitive 1, ≤ | Resistant 1, > | |
Clarithromycin | 0.25 | 0.5 |
Levofloxacin | 1.0 | 1.0 |
Gene | The Primer Sequence | Length (bp) |
---|---|---|
23S rRNA | F: 5′-TAAATACCGACCTGCATGAATG-3′ | 22 |
R: 5′-CTCCATAAGAGCCAAAGCCC-3′ | 20 | |
gyrA | F: 5′-ATCATAGGGCGTGCTTTACC-3′ | 20 |
R: 5′-AAAGGTTAGGCAGACGGCTT-3′ | 20 |
Antibiotic Resistance | Gene | Nucleotide Substitution | N (%) |
---|---|---|---|
Clarithromycin | 23S rRNA | 2142G | 7 (28) |
2143G | 4 (16) | ||
WT * | 14 (56) | ||
Levofloxacin | gyrA | 261A | 3 (12) |
261G | 1 (4) | ||
271A | 4 (16) | ||
272G | 3 (12) | ||
261A, 271A | 2 (8) | ||
WT * | 12 (48) | ||
Both | 23S, gyrA | – | 6 (24) |
Antibiotic | Genetic Testing | Phenotypic Testing | ||
---|---|---|---|---|
Resistant | Sensitive | Resistant | Sensitive | |
Clarithromycin | 11 | 14 | 11 | 14 |
Levofloxacin | 13 | 12 | 14 | 11 |
Total | 25 | 25 |
Antibiotic Resistance | Gene | Nucleotide Substitution | N (%) |
---|---|---|---|
Clarithromycin | 23S rRNA | 2142G | 6 (5) |
2143G | 20 (18) | ||
2142C | 1 (0.9) | ||
WT * | 85 (76) | ||
Levofloxacin | gyrA | 259T | 1 (0.9) |
260T | 1 (0.9) | ||
261A | 11 (9.8) | ||
271A | 7 (6.3) | ||
271T | 4 (3.5) | ||
272G | 2 (1.8) | ||
WT * | 86 (76.8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bodunova, N.; Tsapkova, L.; Polyakova, V.; Baratova, I.; Rumyantsev, K.; Dekhnich, N.; Nikolskaya, K.; Chebotareva, M.; Voynovan, I.; Parfenchikova, E.; et al. Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Curr. Issues Mol. Biol. 2024, 46, 6665-6674. https://doi.org/10.3390/cimb46070397
Bodunova N, Tsapkova L, Polyakova V, Baratova I, Rumyantsev K, Dekhnich N, Nikolskaya K, Chebotareva M, Voynovan I, Parfenchikova E, et al. Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Current Issues in Molecular Biology. 2024; 46(7):6665-6674. https://doi.org/10.3390/cimb46070397
Chicago/Turabian StyleBodunova, Natalia, Larisa Tsapkova, Vera Polyakova, Irina Baratova, Konstantin Rumyantsev, Natalia Dekhnich, Karina Nikolskaya, Margarita Chebotareva, Irina Voynovan, Elena Parfenchikova, and et al. 2024. "Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia" Current Issues in Molecular Biology 46, no. 7: 6665-6674. https://doi.org/10.3390/cimb46070397
APA StyleBodunova, N., Tsapkova, L., Polyakova, V., Baratova, I., Rumyantsev, K., Dekhnich, N., Nikolskaya, K., Chebotareva, M., Voynovan, I., Parfenchikova, E., Pronina, G., Chernikova, E., & Bordin, D. (2024). Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Current Issues in Molecular Biology, 46(7), 6665-6674. https://doi.org/10.3390/cimb46070397